Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen(Heidelberg University), Sascha Dietrich(Heidelberg University)BloodJuly 20, 202210.1182/blood.2021014241Cited by 99SaveCiteExport RISWatch citationsRelated PapersThe ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia|Leukemia|2023|25Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies|Blood Advances|2023|10